Menu
Not yet recruiting NCT07559708

A Study of the Sleepnet Elara APAP Device

No phase Interventional Sleep Apnea - Obstructive

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Sleepnet Elara Treatment.
Who it may be relevant to
Registry conditions: Sleep Apnea - Obstructive. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Prospective, Open-label Study to Assess the Efficacy of the Elara APAP Device When Used in Patients With Obstructive Sleep Apnea

Overview

The goal of this study is to evaluate the effectiveness of the Elara APAP device.

Detailed description

A prospective open label study to assess the efficacy of the Elara APAP device when used in patients with obstructive sleep apnea. Subjects will sign Informed Consent and undergo screening/baseline and a 1 night in-lab PSG.

Interventions

  • Device Sleepnet Elara Treatment
    Subject to have a 1 night in-lab PSG

Primary outcome measures

  • AHI 4% [Time frame: Day 1]

Eligibility criteria

Inclusion criteria

  • Body weight ≥ 30kg
  • Willing and able to consent, adhere to study requirements and receive mask treatment
  • ≥ 18 years of age
  • Diagnosed with OSA (Total AHI >15 events/hr) by a practicing physician within the last 6 months. A re-diagnosis may be necessary to establish current baseline AHI in case there has been significant weight change or other co-morbidities since the previous diagnosis (per PI discretion)
  • Currently utilizing an APAP Device for ongoing treatment of OSA

Exclusion criteria

  • Body weight < 30kg
  • Female currently bearing a child or intending to become pregnant prior to the sleep study.
  • Have implanted pacemaker, ICD or any other medical device that would interfere with the PSG results or safety of the subject undergoing the study
  • Has pneumothorax, pneumomediastinum
  • Has history of Cerebrospinal fluid leakage, craniocerebral trauma, intracranial trauma or pneumocephalus
  • Ongoing shock from various causes untreated
  • Current epistaxis
  • Non-compliant with APAP usage (< 4 hours per night on 70% of nights)
  • Upper gastrointestinal bleeding that has not been effectively controlled
  • Has obstructive vocal cord polyps
  • Severe coronary heart disease with left heart failure
  • Acute otitis media inflammation (must be resolved prior to sleep study)
  • Excessive respiratory secretions and cough weakness
  • Weak spontaneous breathing
  • Tracheal intubation (nasal or oral) and tracheotomy
  • Severe nasal congestion from various causes
  • Lung bullae
  • Central sleep apnea index >5 events/hr
  • Have another significant sleep disorder(s) that in the opinion of the investigator would confound the results of the study (e.g. periodic leg movements >15/hr or insomnia that would interfere with completing the sleep study).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • University Sleep Disorders Center — Auburn

Identifiers

NCT: NCT07559708 · SN-APAP-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗